ZYDUSLIFE Zydus Lifesciences Q4 FY26 results (Jan–Mar 2026) and concall
Zydus Lifesciences concluded FY26 with robust financial performance, reporting 17% YoY revenue growth and record operating profitability. The company saw strong growth across its US, India, and International markets, bolstered by strategic acquisitions like Comfort Click and Amplitude Surgical. Innovation and pipeline advancements, including Desidustat's approval in China and progress in biosimilars, are set to drive future growth, with management guiding for high-teens revenue growth and over 24% EBITDA margins for FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 35.7%, net profit down 38.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,621 | 2,516 | 5,820 | 2,588 | 2,871 +10% | 2,284 −9% | 3,741 −36% |
| EBITDA | 942 | 648 | 3,773 | 585 | 1,152 +22% | 199 −69% | 1,989 −47% |
| Net profit | 790 | 471 | 2,814 | 385 | 1,157 +46% | 296 −37% | 1,722 −39% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
